Goldman downgraded its outlook on MoonLake Immunotherapeutics (MLTX) despite a pipeline update, citing low odds of approval for its lead candidate, sonelokimab, in a pivotal Phase 3 trial. The move reflects growing caution in the biotech sector amid high failure risks.
- Goldman assigns 35% approval probability to sonelokimab, down from 50% previously
- 48% of patients in high-dose arm achieved clear or almost clear skin at Week 16
- 12% discontinuation rate due to adverse events in Phase 3 trial
- MLTX stock trades at $1.20, down 28% from January 2026 levels
- IWM declined 1.4% and XLV dropped 0.6% post-report
- Phase 3 trial readout expected in Q3 2026
Goldman expressed skepticism over the likelihood of regulatory approval for MoonLake Immunotherapeutics' (MLTX) investigational drug sonelokimab, despite the company's recent announcement of positive interim data from its ongoing Phase 3 trial in moderate to severe psoriasis. The firm assigned a 'sell' rating to MLTX, citing a 35% probability of approval based on current trial endpoints and safety profile, down from prior estimates of 50%. The company reported that 48% of patients in the high-dose arm achieved clear or almost clear skin at Week 16, but adverse events led to 12% discontinuation rates—higher than expected for the class. The clinical data, while showing efficacy, did not meet the primary endpoint threshold for statistical significance in the full cohort, which Goldman views as a critical barrier. This follows a pattern of similar setbacks in the dermatology biotech space, with three out of five recent Phase 3 assets failing to gain approval in 2025. The firm noted that the risk-adjusted valuation of MLTX has declined by 28% since the last update, now trading at $1.20 per share, down from $1.68 in January. The broader biotech sector remains sensitive to such developments. MLTX’s performance has historically tracked closely with the IWM (iShares Russell 2000 ETF), which fell 1.4% following the report, while the XLV (Health Care Select Sector SPDR Fund) dipped 0.6%. Small-cap biotech stocks, including those in the dermatology and immunology space, have seen a 12% average decline in market cap since early 2026 as investors reassess trial risk premiums. Investors are now focusing on upcoming data readouts from rival candidates, including those from Pfizer and Novartis, which could influence both regulatory expectations and investor positioning. The outcome of the sonelokimab trial is expected in Q3 2026, with potential implications for MoonLake’s cash runway and partnership prospects.